GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Total Liabilities

MedMira (MedMira) Total Liabilities : $15.31 Mil (As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is MedMira Total Liabilities?

MedMira's Total Liabilities for the quarter that ended in Jan. 2024 was $15.31 Mil.

MedMira's quarterly Total Liabilities increased from Jul. 2023 ($14.14 Mil) to Oct. 2023 ($14.88 Mil) and increased from Oct. 2023 ($14.88 Mil) to Jan. 2024 ($15.31 Mil).

MedMira's annual Total Liabilities declined from Jul. 2021 ($15.65 Mil) to Jul. 2022 ($12.51 Mil) but then increased from Jul. 2022 ($12.51 Mil) to Jul. 2023 ($14.14 Mil).


MedMira Total Liabilities Historical Data

The historical data trend for MedMira's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Total Liabilities Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.51 14.05 15.65 12.51 14.14

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.82 13.27 14.14 14.88 15.31

MedMira Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

MedMira's Total Liabilities for the fiscal year that ended in Jul. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=11.904+(2.238+-4.4408920985006E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=14.14

Total Liabilities=Total Assets (A: Jul. 2023 )-Total Equity (A: Jul. 2023 )
=2.764--11.378
=14.14

MedMira's Total Liabilities for the quarter that ended in Jan. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=13.338+(1.969+1.1102230246252E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=15.31

Total Liabilities=Total Assets (Q: Jan. 2024 )-Total Equity (Q: Jan. 2024 )
=3.326--11.98
=15.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedMira Total Liabilities Related Terms

Thank you for viewing the detailed overview of MedMira's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

MedMira Reports First Quarter Results FY2023

By ACCESSWIRE ACCESSWIRE 12-31-2022

MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test

By ACCESSWIRE ACCESSWIRE 01-11-2023

MedMira Reports 2019 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 11-29-2019

MedMira Reports Second Quarter Results

By GlobeNewswire GlobeNewswire 03-30-2018

MedMira Reports First Quarter Results FY2020

By GlobeNewswire GlobeNewswire 12-31-2019

MedMira Reports First Quarter Results FY2024

By ACCESSWIRE 12-30-2023

MedMira Reports First Quarter Results FY2022

By GlobeNewswire GlobeNewswire 12-31-2021